Results 101 to 110 of about 6,415 (210)

Anidulafungin in the treatment of patients with invasive candidiasis

, 2008
Echinocandins have emerged as important agents for the treatment of invasive candidiasis. Forthcoming guidelines are expected to recommend an echinocandin agent as initial primary therapy in patients who are severely ill and/or have risk factors for ...
Cubillos, G Fernando, Kett, Daniel H
core   +1 more source

Pharmacokinetics of Anidulafungin in Pleural Fluid during the Treatment of a Patient with Candida Empyema

, 2011
Candida empyema is a serious complication of disseminated candidiasis. However, little is known about the intrapleural pharmacokinetics of echinocandins. We report the penetration of anidulafungin into the pleural fluid of a patient with
A. John Barrett, Thomas J. Walsh, Juan Gea-Banacloche, Adrian M. Zelazny, Michael G. Rinaldi, Scott R. Penzak, Robert L. Danner, Marisa Ditullio, Gennethel Pennick, Brad Moriyama, Eleanor Wilson, Stacey A. Henning   +11 more
core   +1 more source

Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin

, 2020
BACKGROUND: Case reports and pharmacokinetic data suggest off-label echinocandin dosing may be needed to reach adequate serum concentrations in obese patients. Few outcome studies exist evaluating this population.
Davis, Susan L, Kenney, Rachel M, Hutton, Mary, Vazquez, Jose A   +3 more
core  

Multicenter evaluation of low inoculum and a colorimetric assay for antifungal susceptibility testing of Aspergillus fumigatus to echinocandins with the EUCAST E.Def 9.4

Journal of Clinical Microbiology
Echinocandin minimal effective concentration (MEC) determination for Aspergillus is challenging with the EUCAST method. We investigated the applicability of a lower inoculum (103 CFU/mL) and a colorimetric assay for micafungin and anidulafungin against ...
Joseph Meletiadis, Maria Siopi, Karin Meinike Jørgensen, Pilar Escribano, Jesus Guinea, Maiken Cavling Arendrup   +5 more
doaj   +1 more source

An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America

, 2014
Incidence and mortality of candidaemia/invasive candidiasis (C/IC) is relatively high in Latin America versus North America and Europe. To assess efficacy and safety of intravenous (IV) anidulafungin in Latin American adults with documented C/IC.
Nucci, Marcio, Colombo, Arnaldo L. [UNIFESP], Abreu, Paula, Magana, Martin, Petti, Marco, Schlamm, Haran T., Sanchez, Sonia P.   +6 more
core   +1 more source

The in vitro efficacy of Anidulafungin with and without Nikkomycin Z against C. auris isolates.

This thesis investigates the in vitro antifungal efficacy of anidulafungin alone and in combination with nikkomycin Z against 15 Candida auris isolates representing four major genetic clades. Candida auris is a multidrug-resistant pathogen posing serious
Amano, Chiaki
core  

Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata

, 2012
The aim of this study was to compare the in vitro and in vivo activities of micafungin, caspofungin, and anidulafungin against Candida glabrata. The MICs against 28 clinical isolates showed that the overall susceptibilities to caspofungin and to ...
Orlando F., Manso E., Spreghini E., Giannini D., Posteraro B., Posteraro, Brunella, BARCHIESI, FRANCESCO, Sanguinetti, Maurizio, Sanguinetti M.   +8 more
core   +1 more source

Comparison of antifungal drugs in the treatment of invasive pulmonary aspergillosis: a systematic review and network meta-analysis

Frontiers in Microbiology
BackgroundVoriconazole, isavuconazole, and amphotericin (AmB) formulations are currently recommended to treat invasive pulmonary aspergillosis (IPA).
Jing Cheng, Hedong Han, Wenwen Kang, Zijin Cai, Ping Zhan, Tangfeng Lv   +5 more
doaj   +1 more source

Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies

, 2017
Concerns with echinocandin use for infections caused by Candida parapsilosis complex species have driven the need for data to support echinocandin clinical efficacy in such patients.
Marcio Nucci, Aram J., Kontoyiannis D. P., Patricia A. Hogan, Hogan, Patricia A., Yan J. L., BASSETTI, MATTEO, Jalal Aram, Aram, Jalal, Yan, Jean L., Capparella M. R., Nucci, Marcio, Jean L. Yan, Hogan P. A., Matteo Bassetti, Bassetti M., Nucci M., Capparella, Maria Rita, Kontoyiannis, Dimitrios P, Dimitrios P. Kontoyiannis, Maria Rita Capparella   +20 more
core   +1 more source

Dynamics of Anidulafungin use in a Tertiary Care Hospital [PDF]

Journal of Clinical and Diagnostic Research, 2014
Zeliha Kocak Tufan, Rahmet Guner, Tumer Guven, Gul Ruhsar Yilmaz, Mehmet A. Tasyaran   +4 more
doaj   +1 more source